Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus epacadostat versus pembrolizumab plus placebo in cisplatin-ineligible urothelial carcinoma
NL-OMON44517Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab and epacadostat in transitional cell carcinoma (TCC) and bladder cancer, sponsored by Merck & Co. Started Feb 2018; status: active, not recruiting.
02
Drugs
pembrolizumabepacadostat
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON44517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44517.